Synthesis, cytotoxicity and mechanistic evaluation of 4-oxoquinoline-3- carboxamide derivatives: Finding new potential anticancer drugs

Article abstract of DOI:10.3390/molecules19056651

As part of a continuing search for new potential anticancer candidates, we describe the synthesis, cytotoxicity and mechanistic evaluation of a series of 4-oxoquinoline-3-carboxamide derivatives as novel anticancer agents. The inhibitory activity of compounds 10-18 was determined against three cancer cell lines using the MTT colorimetric assay. The screening revealed that derivatives 16b and 17b exhibited significant cytotoxic activity against the gastric cancer cell line but was not active against a normal cell line, in contrast to doxorubicin, a standard chemotherapeutic drug in clinical use. Interestingly, no hemolytical activity was observed when the toxicity of 16b and 17b was tested against blood cells. The in silico and in vitro mechanistic evaluation indicated the potential of 16b as a lead for the development of novel anticancer agents against gastric cancer cells.

Full text of DOI:10.3390/molecules19056651

Molecules 2014, 19, 6651-6670; doi:10.3390/molecules19056651
OPEN ACCESS
molecules
ISSN 1420-3049
www.mdpi.com/journal/molecules
Article
Synthesis, Cytotoxicity and Mechanistic Evaluation of
4-Oxoquinoline-3-carboxamide Derivatives:
Finding New Potential Anticancer Drugs
Luana da S. M. Forezi 1, Nathalia M. C. Tolentino 1, Alessandra M. T. de Souza 2,
Helena C. Castro 3, Raquel C. Montenegro 4, Rafael F. Dantas 5, Maria E. I. M. Oliveira 5,
Floriano P. Silva, Jr. 5, Leilane H. Barreto 4, Rommel M. R. Burbano 4, Bárbara Abrahim-Vieira 2,
Riethe de Oliveira 2, Vitor F. Ferreira 1, Anna C. Cunha 1, Fernanda da C. S. Boechat 1
and Maria Cecília B. V. de Souza 1,*
1
Outeiro de São João Batista, Fluminense FederalUniversity (UFF), s/n, Niterói 24020141,
RJ, Brazil
2
Laboratory of Molecular Modeling & QSAR (ModMolQSAR), Federal University of Rio de
Janeiro (UFRJ), Rio de Janeiro 21949-900, RJ, Brazil
3
LABIEMol, Outeiro de São João Batista, Fluminense Federal University, s/n,
Niterói 24020-141, RJ, Brazil
4
Institute of Biological Sciences, Federal University of Pará, Av. Augusto Corrêa, n.01—Guamá,
Belém, 66075-110, Pará, Brazil
5
Laboratory of Biochemistry of Proteins and Peptides, Oswaldo Cruz Institute, FIOCRUZ,
Rio de Janeiro 21040-900, RJ, Brazil
* Author to whom correspondence should be addressed; E-Mail: gqocica@vm.uff.br;
Tel.: +55-21-2629-2138; Fax: +55-21-2629-2144.
Received: 25 March 2014; in revised form: 1 May 2014 / Accepted: 12 May 2014 /
Published: 22 May 2014
Abstract: As part of a continuing search for new potential anticancer candidates,
we describe the synthesis, cytotoxicity and mechanistic evaluation of a series of
4-oxoquinoline-3-carboxamide derivatives as novel anticancer agents. The inhibitory
activity of compounds 10–18 was determined against three cancer cell lines using the
MTT colorimetric assay. The screening revealed that derivatives 16b and 17b exhibited
significant cytotoxic activity against the gastric cancer cell line but was not active against a
normal cell line, in contrast to doxorubicin, a standard chemotherapeutic drug in clinical
use. Interestingly, no hemolytical activity was observed when the toxicity of 16b and 17b
was tested against blood cells. The in silico and in vitro mechanistic evaluation indicated

Molecules 2014, 19
the potential of 16b as a lead for the development of novel anticancer agents against gastric
6652
cancer cells.
Keywords: 4-oxoquinoline; carboxamide; heterocycles; anticancer
1. Introduction
Currently, most treatments against cancer are multimodal, involving chemotherapy, radiation and
surgery to treat tumors. However, due to the present limitations associated with standard chemotherapy,
including side effects and acquired tumor resistance, there is an urgent need to discover new anticancer
agents with improved therapeutic profiles. Despite these issues, chemotherapy continues to be the most
prevalent pharmacological approach for the treatment of cancer [1].
Oxoquinolines are a class of compounds with important biological activities [2–4]. They represent
an important group of heterocyclic compounds because of their pharmacological activities against
bacterial infections [5].
The mechanism of the antibacterial activity of 4-oxoquinolines involves modulation of prokaryotic
type II topoisomerases (DNA gyrase and topoisomerase IV), and they cause cell death by generating
high levels of double-stranded DNA breaks. These enzymes are homologous to human type II
topoisomerases, which modulate the topological state of the genetic material by passing an intact
DNA helix through a transient double stranded break generated in a separate part of DNA. Thus,
4-oxoquinolines may also exhibit anticancer activity through the same mechanism [6–9].
In the last several decades, the described new 4-oxoquinoline derivatives were able to reduce
mortality when administered as prophylaxis for infections in cancer patients [6,7,10–13] and with
feasible anticancer profile. According to the literature [10], the mechanism of action may be related to
the inhibition of mammalian topoisomerase II, which is a target of many antitumor agents. Interestingly,
some 4-oxoquinolines show antineoplastic activity as high as etoposide, an anticancer drug.
Some oxoquinoline derivatives and analogues have shown interesting antimitotic profiles
(Figure 1) [14,15]. Notably, voreloxin (6) [8,16] is an 4-oxoquinoline analogue that shows anticancer
activity by intercalating in DNA and affecting topoisomerase II [6,7,10]. Currently, this compound is
undergoing pre-clinical evaluation [8,16].
In the continuing search for more selective anticancer agents, many research groups worldwide are
conducting research concerning structural modification of the oxoquinolinic core to obtain more potent
drugs with fewer side effects. Herein, we report the synthesis, the biological and theoretical
evaluations of a series of 4-oxoquinoline derivatives as investigational anticancer agents and explore
the mechanism of action of these molecules.
2. Results and Discussion
2.1. Chemistry
As shown in the Scheme 1, the derivatives were synthesized using a three-step procedure that
involves the condensation of anilines 7 with diethyl ethoxymethylenemalonate (EMME)in refluxing

Molecules 2014, 19
6653
ethanol followed by thermal cyclization of the aniline acrylate intermediates 8, according to Gould-
Jacobs methodology [17–21]. A nucleophilic substitution reaction between oxoquinolines 9 and the
appropriate amines in diphenyl ether as solvent affords the respective carboxamides 10–18
(Table 1) in 30%–98% yields. Their structures (new compounds) were confirmed by IR, NMR and
mass spectroscopy. The HPLC analysis of 16b and 17b was also performed.
Figure 1. Structures of voreloxin (6) and several oxoquinoline derivatives 1–5 with
anticancer activity.
Scheme 1. Synthesis of 4-oxoquinolines 10–18.
Reagents and conditions: (a) diethyl ethoxymethylenemalonate (EMME), ethanol, reflux; (b)
diphenyl ether, reflux; (c) diphenyl ether, amine, 210 °C.
2.2. Evaluation of Anticancer Activity in Vitro
All oxoquinolinecarboxamides 10–18 were evaluated in vitro against three cancer cell lines from
different origins: colon (HCT-116), stomach (ACP03) and breast (MDAMB-231). The toxicological
profiles of the active derivatives (IC50 < 20 μM) were also evaluated by testing on a normal fibroblast
cell line (MRC-5) and erythrocytes. The concentration that inhibits 50% of cell growth (IC50) was

Molecules 2014, 19
6654
reported in μM, and the hemolytic potential is expressed in μg/mL (Table 2). Finally, a total of
24 derivatives were evaluated, and doxorubicin [22] was used as a positive control.
Table 1. Yields and melting points of 4-oxoquinolines 10–18.
Derivative
10a
R
H
R1
Yield (%)
MP (°C)
244–246
262–263
96
85
10b
6-Cl
10c
7-Cl
79
220–221
11a
11b
11c
12a
H
30
58
75
96
209–212
140–142
140–141
>300
6-Cl
7-Cl
H
12b
13a
13b
14a
14b
6-Cl
H
98
94
80
86
87
>300
>300
7-Cl
H
>300
>300
7-Cl
270–273
15a
15b
15c
16a
16b
H
79
85
83
94
96
>300
>300
>300
>300
>300
6-Cl
7-Cl
H
6-Cl
16c
7-Cl
86
>300
17a
17b
17c
18a
18b
18c
H
66
98
63
57
44
45
>300
>300
6-Cl
7-Cl
H
>300
250–251
256–258
261–262
6-Cl
7-Cl
Derivatives 16b and 17b displayed cytotoxicity against the gastric cancer cell line, with IC50 values
of 1.92 and 5.18 μM, respectively (Table 2). However, in normal fibroblasts, they did not display
cytotoxicity at 20 µM. Although the IC50 of doxorubicin was lower than those of 16b and 17b, these
derivatives were ten times more selective against cancer cells than to normal cells (Figure 2);
doxorubicin shows no selectivity between cancer and normal cells (Table 2 and Figure 2).
Hemolytic activity is an acute toxic effect that must be analyzed when evaluating any new oral
or intravenous drug. Therefore, we performed a hemolytic assay in mice erythrocytes to evaluate
nonspecific damage to plasma membranes. Importantly, no hemolytic activity (EC50 > 200 µg/mL)
was observed for any of the tested derivatives, suggesting that the cytotoxicity against cancer cell lines
is not related to membrane damage.

Molecules 2014, 19
6655
Table 2. Cytotoxic activity of 10–18 on cancer cell lines (ACP-03, HCT-116 and MDA-
MB-231), a normal fibroblast cell line (MRC-5) and erythrocytes (to measure hemolysis).
Hemolysis
Derivatives
IC50 µM
(μg/mL)
ACP-03
HCT-116
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
MDAMB231
>10
MRC5
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
>20
ND
ND
>20
ND
ND
ND
ND
10a
10b
10c
11a
11b
11c
12a
12b
13a
13b
14a
14b
15a
15b
15c
16a
16b
16c
17a
17b
17c
18a
18b
18c
>10
>200
>200
>200
>200
>200
>200
>200
>200
>200
>200
>200
>200
>200
>200
>200
>200
>200
>200
>200
>200
>200
>200
>200
>200
>200
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
>10
1.92 (1.39–2.66)
>10
>10
>10
>10
>10
5.18 (3.61–7.45)
>10
>10
>10
>10
>10
>10
>10
>10
>10
DOXORUBICIN 0.274 (0.22–0.33) 0.1 (0.047–0.28) 0.43 (0.36–0.52) 0.2 (0.16–0.25)
Data are presented as the IC50 values, and 95% confidence intervals were obtained by nonlinear regression for
all cell lines (gastric (ACP03), colon (HCT-116), breast (MDAMB231), and normal human fetal lung
fibroblast (MRC5)) from three independent experiments. Doxorubicin (Dox) was used as the positive control.
Experiments were performed in triplicate. IC50 = concentrations that result in 50% inhibition of cell growth,
in μM. ND—Not determined.
2.3. In Silico Mechanism Analysis: Topoisomerase II as a Feasible Target
Previous studies have shown that voreloxin [8,16], a first-in-class cytotoxic 4-oxoquinoline
analogue, intercalates into DNA and inhibits topoisomerase II [6,7]. Based on these results, we
investigated the feasibility of this mechanism by docking the most actives derivatives 16b and 17b,
into the DNA binding site of topoisomerase II (Figure 3).

Molecules 2014, 19
Figure 2. Comparison of the IC50values of derivatives against a gastric cancer cell line
6656
(ACP-03) and normal fibroblast cell line (MRC-5).
25
*
**
20
15
10
5
ACP-03
MRC-5
**
*
0
Dox
16b
17b
* p < 0.001, ** p < 0.05, ANOVA (two way), followed by Bonferroni test.
The validity of the docking accuracy was evaluated by redocking using the crystal structure of
topoisomerase II (PDB ID: 3QX3 complexed with etoposide, an inhibitor) as described in the
experimental section. The reliability of the docking protocol was first checked by comparing the best
docking position of the inhibitor with its crystal structure that was obtained using the GOLD program.
The comparison of the redocking results with the co-crystallized conformation was performed using
the program Pymol. The in silico analysis revealed a conformation similar to the crystallized structure
with a root mean square deviation (RMSD) of 0.14 Å. These data supported the hypothesis that the
experimental binding mode could be accurately reproduced using this protocol.
The molecular docking data showed that the carbonyl group in the heterocyclic ring of 16b interacts
via a hydrogen bond with the GLN778 residue of the enzyme (O-O 3.9 Å) (Figure 3A) and the same
ring of 17b interacts (O-N 2.8 Å). Similarly, hydrogen bond interactions were also observed between
the inhibitor and cytosine (−1), guanine (+5) and thymine (+1) at distances of 3.5, 4.1 and 5.3 Å,
respectively for 16b, while for 17b were 2.7, 4.0 and 5.2Å between cytosine (−1), guanine (+5),
adenosine (+4), respectively. The literature reports that etoposide interacts with the enzyme and with
DNA [23]. Interestingly, whereas etoposide interacts through extensive contacts, 16b and 17b have a
smaller molecular volume and interacts only with the GLN778 residue of the enzyme. This interaction
seems to contribute to the stabilization of the complex formed by this ligand and the topoisomerase II.
Similar to etoposide [24], these derivatives bind between the base pairs showed, possibly preventing
their stacking and consequently blocking the re-ligation of the cleaved phosphodiester bond between
the nucleotides. However, 17b showed no parallel position interactions when compared with 16b,
probable due to the effect of ortho-chlorine substitution. Thereat, weak interactions were observed,
supporting its lower activity than 16b.

Molecules 2014, 19
Figure 3. Molecular docking of 16b (A) and 17b (B) in the topoisomerase II binding site:
6657
The cartoon-and-stick representation shows the insertion of 16b (in red) and 17b (in pink)
as well as the hydrogen bonds (in green) between the GLN778 residue of the enzyme (in
yellow) and the nucleotides(Adn, adenosine; Cyt, cytosine; Thy, thymine; Gua, guanine).
+5 Gua
3.9 Å
4.1 Å
A
3.5 Å
1.0 Å
GLN778
+1 Thy
-1 Cyt
+4 Adn
+5 Gua
B
5.2 Å
2.7 Å
2.8 Å
4.0 Å
GLN778
-1 Cyt
2.4. In Vitro Mechanistic Evaluation: Topoisomerase II as a Target
To confirm the theoretical data, we performed a topoisomerase II relaxation assay in the presence of
16b and 17b (Figure 4). The gel bands represent the different conformational forms of pRYG after
the reaction catalyzed by topoisomerase II alone (lanes E, F and G) or pre-incubated with 100 µM 16 b,
17b or VP-16 (etoposide) (lanes A, B and H). The electrophoresis conditions of this experiment,
specifically the absence of ethidium bromide, allowed the supercoiled (SC) form of pRYG to migrate
as a single band on the gel. The addition of topoisomerase II unwinds the SC-producing topoisomers
(Rn) and is shown in the gel as discrete bands that migrate slower than SC. In the presence of 16b, 17b
or VP-16, only the SC band is observed, which indicates topoisomerase inhibition. These results
support in the in silico docking evaluation pointing this enzyme a target for these new derivatives.

Molecules 2014, 19
Figure 4. Effects of 16b and 17b on the inhibition of supercoiled DNA relaxation
6658
promoted by topoisomerase II. Supercoiled DNA (pRYG, 200 ng) was incubated
with topoisomerase II (10 U) in the presence of the derivatives and then analyzed on
an agarose gel without ethidium bromide. Lanes A and B, supercoiled DNA incubated with
topoisomerase II and 100 µM of compounds 16b or 17b, respectively; lane C, ladder; lane D,
supercoiled DNA without enzyme; lanes E,F,G, supercoiled DNA incubated with enzyme
alone; lane H, supercoiled DNA with topoisomerase II in the presence of 100 μM VP-16.
The arrow indicates the supercoiled (SC) DNA band, and the brackets indicate the
topoisomer bands (Rn).
Figure 5. Comparison of 16b and 17b with anticancer marketed drugs, cisplatin
and fluorouracil, (A) “Druglikeness”; and (B) in silico toxicity values calculated by
using the Osiris Program and the physico-chemical parameters considering Lipinski’s
rule-of-five paradigm.
2.5. In Silico Pharmacokinetic Analysis
In this work we also assessed 16b and 17b pharmacokinetic properties by using in silico evaluation.
Because significant absorption is necessary for oral administration, we analyzed this derivative
according to the “rule-of-five” developed by Lipinski and co-workers [25].The rule-of-five indicates
the theoretical potential of a chemical compound to exhibit satisfactory oral bioavailability. The rule
states that the most “druglike” molecules have a clog P ≤ 5, molecular weight (MW) ≤ 500, number of

Molecules 2014, 19
6659
hydrogen bond acceptors (HBA) ≤ 10 and number of hydrogen bond donors (HBD) ≤ 5. Molecules
violating more than one of these rules may show a low bioavailability profile. The results showed
that compound 16b and 17b fulfilled the Lipinski “rule-of-five” (Figure 5). The “druglikeness test”
calculation that evaluates the profile of the derivative as a drug, showed 16b and 17b with the better
values than marketed drugs such as cisplatin and fluorouracil. Finally, according to our in silico
toxicity evaluation of tumorigenic, irritant, mutagenic and reproductive effects, and compound 16b
showed low profile for these toxicity effects (Figure 5). It is important to note that the toxicity
predicted herein neither is a fully reliable toxicity prediction nor guarantees that these compounds are
completely free of any toxic effects. However, it reinforced the promising profile of 16b for further
experimental evaluation.
3. Experimental
3.1. General Information
1H-NMR spectra were recorded on a Varian Unity Plus 300 spectrometer operating at 200.00 MHz,
300.00 MHz or 500.00 MHz (1H) and 50.0 MHz, 75.0 MHz or 125.0 MHz (13C), using CDCl3 or
DMSO-d6 as the solvent. Chemical shifts were reported in parts per million (ppm) relative to the
internal standard tetramethylsilane (TMS). Signals were designated as follows: brs, broad singlet;
s, singlet; d, doublet; dd, doublet of doublets; t, triplet; q, quartet; m, multiplet. Hydrogen and carbon
NMR spectra were typically obtained at room temperature. The two-dimensional experiments were
acquired using standard Varian Associates automated programs for data acquisition and processing.
The IR spectra were recorded on a Perkin-Elmer FT-IR 1600 spectrometer using potassium bromide
pellets, and frequencies were expressed in cm−1. Mass spectra were obtained with ESI (MICRO-TOF
BRUKER DALTONICS). The HPLC analysis was performed using a Dionex Ultimate 3000 HPLC
System with a DAD Detector. Analyteevaluation was carried out with an Acclaim 120 C18column (3 μm,
150 × 4.6 mm), provided by Dionex (Sunnyvale, CA, USA).The melting points were determined with
a Fisher-Johns apparatus and were uncorrected. All solvents and reagents were purchased from
commercial sources: Sigma-Aldrich Brazil (São Paulo, Brazil), Acros Organics (Geel, Belgium) and
Tedia Brazil (Rio de Janeiro, Brazil).
3.2. Synthesis
3.2.1. General Procedure for the Synthesis of Anilinomethylenemalonates 8a–c
A solution of the appropriate aniline (100 mmol), and diethyl ethoxymethylenemalonate(20.4 mL,
100 mmol) was heated under reflux for 3 h. The mixture was allowed to cool and then was poured into
ice-cold water (100 g). The precipitate was collected by filtration and recrystallized from hexane to
give derivatives 8a–c [20,26,27].
Diethyl 4-chloroanilinomethylenemalonate (8a): yield: 22.4 g (90%) as white crystals; m.p.: 80–81 °C;
1H-NMR (200.00 MHz, CDCl3) δ (ppm): 11.01 (1H, d, J = 13.5 Hz, N-H), 8.46 (1H, d, J = 13.5 Hz,
H-β), 7.37–7.31 (2H, m, H-2 and H-6), 7.11–7.04 (2H, m, H-3 and H-5), 4.32 (2H, q, J = 7.2 Hz,

Molecules 2014, 19
6660
OCH2CH3), 4.26 (2H, q, J = 7.2 Hz, OCH2CH3), 1.39 (3H, t, J = 7.2 Hz, OCH2CH3), 1.34 (3H, t,
J = 7.2 Hz, OCH2CH3); IR (KBr) ν (cm−1): 1721 and 1675 (C=O), 1262 (C-O).
Diethyl 3-chloroanilinomethylenemalonate (8b): yield: 22.6 g (91%) as white crystals; m.p.: 57–58 °C;
1H-NMR (200.00 MHz, CDCl3) δ (ppm): 10.99 (1H, d, J = 12.9 Hz, N-H), 8.45 (1H, d, J = 13.5 Hz,
H-β), 7.10 (1H, dd, J = 2.1 and 0.9 Hz, H-2), 7.12–7.15 (1H, m, H-4), 7.30 (1H, t, J = 8.1 Hz, H-5), 7.01
(1H, ddd, J = 8.1, 2.1 and 1.2 Hz, H-6), 4.31 (2H, q, J = 7.2 Hz, OCH2CH3), 4.25 (2H, q, J = 7.2 Hz,
OCH2CH3), 1.38 (3H, t, J = 7.2 Hz, OCH2CH3), 1.33 (3H, t, J = 7.2 Hz, OCH2CH3); IR (KBr) ν (cm−1):
1713 and 1688 (C=O), 1256 (C-O).
Diethyl anilinomethylenemalonate (8c): yield: 24.8 g (82%) as white crystals; m.p.: 46–48 °C;
1H-NMR (200.00 MHz, CDCl3) δ (ppm): 11.21 (1H, d, J = 13.2 Hz, N-H), 8.51 (1H, d, J = 13.5 Hz,
H-β), 7.90–7.20 (5H, m, Ph), 4.32 (2H, q, J = 7.2 Hz, OCH2CH3), 4.25 (2H, q, J = 7.2 Hz, OCH2CH3),
1.38 (3H, t, J = 7.2 Hz, OCH2CH3), 1.33 (3H, t, J = 7.2 Hz, OCH2CH3); IR (KBr) ν (cm−1): 1718 and
1675 (C=O), 1261 (C-O).
3.2.2. General Procedure for the Synthesis of Oxoquinolines 9a–c
Anilinomethylenemalonates 8a–c (3 g, 10.83 mmol) were refluxed for 30 min in
diphenyl ether (30 mL), leading to crudeoxoquinolines 9a–c which were recrystallized from
dimethylformamide [20,21,26,27].
3-Carbethoxy-6-chloro-1,4-dihydro-4-oxoquinoline (9a): yield: 2.1 g (85%) as white crystals; m.p.:
295–296 °C; 1H-NMR (300.00 MHz, DMSO-d6) δ (ppm): 8.65 (1H, s, H-2), 8.22 (1H, d, J = 2.4 Hz, H-5),
7.85 (1H, dd, J = 9,0 and 2.4 Hz, H-7), 7.78 (1H, d, J = 8.7 Hz, H-8), 4.36 (2H, q, J = 6.9 Hz,
OCH2CH3), 1.42 (3H, t, J = 6.9 Hz, OCH2CH3); IR (KBr) ν (cm−1): 3300–2800 (OH/NH), 1688 (C=O).
3-Carbethoxy-7-chloro-1,4-dihydro-4-oxoquinoline (9b): yield: 2.0 g (80%) as white crystals; m.p.:
293–294 °C; 1H-NMR (300.00 MHz, DMSO-d6) δ (ppm): 8.71 (1H, s, H-2), 8.26 (1H, d, J = 8.7 Hz, H-5),
7.59 (1H, dd, J = 9.0 and 2.1 Hz, H-6), 7.79 (1H, d, J = 2.1 Hz, H-8), 4.33 (2H, q, J = 6.9 Hz,
OCH2CH3), 1.39 (3H, t, J = 6.9 Hz, OCH2CH3); IR (KBr) ν (cm−1): 3300–2800 (OH/NH), 1690 (C=O).
3-Carbethoxy-1,4-dihydro-4-oxoquinoline (9c): yield: 2.1 g (83%) as white crystals; m.p.: 268–269 °C;
1H-NMR (300.00 MHz, DMSO-d6) δ (ppm): 8.65 (1H, s, H-2), 8.22 (1H, d, J = 2.4 Hz, H-5),
7.85 (1H, dd, J = 9.0 and 2.4 Hz, H-7), 7.78 (1H, d, J = 8.7 Hz, H-8), 7.49 (1H, m, H6), 4.36 (2H, q,
J = 6.9 Hz, OCH2CH3), 1.42 (3H, t, J = 6.9 Hz, OCH2CH3); IR (KBr) ν (cm−1): 3300–2800 (OH/NH),
1695 (C=O).
3.2.3. General Procedure for the Synthesis of Oxoquinolines 10–18
Oxoquinolines 9a–c(8 mmol) were reacted with the appropriate amine (8 mmol) in diphenyl ether
(30 mL) at 210 °C under magnetic stirring for 1 h. The resulting mixture was poured into petroleum
ether. The obtained solid was filtered and recrystallized from dichloromethane/petroleum ether (1/1) to
yield the derivatives listed below [28–30].

Molecules 2014, 19
6661
4-Oxo-N'-(4-chlorobenzyl)-1,4-dihydroquinoline-3-carboxamide (10a): yield: 1.4 g (96%) as a light
1
brown solid; m.p.: 244–246 °C; H-NMR (500.00 MHz, DMSO-d6) δ (ppm): 10.43 (1H, t, J = 5.9 Hz,
C=ONH), 8.75 (1H, s, H-2), 8.26 (1H, dd, J = 8.5 and 0.9 Hz, H-5), 7.77 (1H, ddd, J = 8.3, 6.8 and
1.5 Hz, H-7), 7.69 (1H, dd, J = 8.3 and 0.7 Hz, H-8), 7.48 (1H, ddd, J = 8.1, 6.8 and 1.3 Hz, H-6),
7.42-7.34 (4H, m, H-2', H-3', H-5' and H-6'), 4.56 (2H, d, J = 6.0 Hz, NHCH2); 13C-NMR (125.0 MHz,
DMSO-d6) δ (ppm): 176.0, 164.5, 143.6, 139.1, 138.6, 132.5, 129.1, 128.2, 126.1, 125.3, 124.8, 118.9,
110.6, 41.3; IR (KBr) ν (cm−1): 3160 (N-Hamide), 3066 (C-Harom), 1636 (C=Oketone), 1603 (C=Oamide).
6-Chloro-4-oxo-N'-(4-chlorobenzyl)-1,4-dihydroquinoline-3-carboxamide (10b): yield: 1.2 g (85%) as a
light brown solid; m.p.: 262–263 °C; 1H-NMR (500.00 MHz, DMSO-d6) δ (ppm): 10.58 (1H, t, J = 5.8 Hz,
C=ONH), 8.79 (1H, s, H-2), 8.15 (1H, t, J = 1.5 Hz, H-7), 7.69 (1H, d, J = 1.8 Hz, H-5), 7.36 (5H, m,
13
H-8, H-2', H-3', H-5' and H-6'), 4.53 (2H, d, J = 2.7 Hz, NHCH2); C-NMR (125.0 MHz, DMSO-d6) δ
(ppm): 174.2, 165.2, 146.3, 140.6, 138.8, 131.6, 131.2, 129.6, 129.1, 128.7, 128.2, 128.1, 127.6, 110.3,
43.3; IR (KBr) ν (cm−1): 3150 (N-Hamide), 3054 (C-Harom), 1631 (C=Oketone), 1605 (C=Oamide).
7-Chloro-4-oxo-N'-(4-chlorobenzyl)-1,4-dihydroquinoline-3-carboxamide (10c): yield: 1.1 g (79%) as
1
a light brown solid; m.p.: 220–221 °C; H-NMR (500.00 MHz, DMSO-d6) δ (ppm): 10.42 (1H, t,
J = 5.8 Hz, C=ONH), 8.89 (1H, s, H-2), 8.34 (1H, d, J = 8.5 Hz, H-5), 7.85 (1H, m, H-8), 7.59 (1H, m,
13
H-6), 7.48 (4H, d, J = 7.3 Hz, H-2', H-3', H-5' and H-6'), 4.71 (2H, d, J = 6.1 Hz, NHCH2); C-NMR
(125.0 MHz, DMSO-d6) δ (ppm): 175.5, 164.3, 144.5, 139.9, 138.5, 137.2, 131.3, 129.1, 128.3, 127.6,
125.2, 124.7, 118.2, 111.2, 41.4; IR (KBr) ν (cm−1): 3150 (N-Hamide), 3052 (C-Harom), 1655 (C=Oketone),
1627 (C=Oamide).
4-Oxo-N'-cyclohexyl-1,4-dihydroquinoline-3-carboxamide (11a): yield: 0.4 g (30%) as a white solid;
1
m.p.: 209–212 °C; H-NMR (500.00 MHz, DMSO-d6) δ (ppm): 10.10 (1H, d, J = 7.7 Hz, C=ONH),
8.75 (1H, s, H-2), 8.30 (1H, dd, J = 8.2 and 1.1 Hz, H-5), 7.81–7.77 (1H, m, H-7), 7.72 (1H, d, J = 8.1
Hz, H-8), 7.53-7.48 (1H, m, H-6), 3.89 (1H, m, H-1'), 1.89 (2H, m, H-2' axial and H-6axial), 1.72 (2H, dd,
J = 9.3 and 3.7 Hz, H-3'
and H-5'axial), 1.59 (1H, dd, J = 9.3 and 3.2 Hz, H-4'), 1.39 (5H, m,
axial
H-2'equatorial, H-3'equatorial, H-4'equatorial, H-5'equatorial, H-6'equatorial); 13C-NMR (125.0 MHz, DMSO-d6) δ
(ppm): 176.1, 163.3, 143.3, 139.0, 132.4, 126.1, 125.3, 124.7, 118.8, 111.0, 46.6, 32.4, 25.2, 24.0;
IR (KBr) ν (cm−1): 3433 (N-Hamide), 1644 (C=Oketone), 1617 (C=Oamide).
6-Chloro-4-oxo-N'-cyclohexyl-1,4-dihydroquinoline-3-carboxamide (11b): yield: 1.4 g (58%) as a
1
white solid; m.p.: 140–142 °C; H-NMR (500.00 MHz, DMSO-d6) δ (ppm): 9.91 (1H, d, J = 7.8 Hz,
C=ONH), 8.73 (1H, s, H-2), 8.17 (1H, d, J = 2.3 Hz, H-5), 7.77 (1H, dd, J = 8.8 and 2.3 Hz, H-7),
7.72 (1H, d, J = 8.8 Hz, H-8), 3.84 (1H, m, H-1'), 1.87 (2H, m, H-2'axial and H-6'axial), 1.67 (2H, m,
H-3'axial and H-5'axial), 1.55 (2H, m, H-4'), 1.35 (4H, m, H-2'equatorial, H-3'equatorial, H-5'equatorial
,
13
H-6'equatorial); C-NMR (125.0 MHz, DMSO-d6) δ (ppm): 174.9, 162.9, 143.7, 137.7, 132.5, 129.4,
127.1, 124.2, 121.3, 111.3, 46.7, 32.4, 25.1, 24.0; IR (KBr) ν (cm−1): 3459 (N-Hamide), 3063 (C-Harom),
1651 (C=Oketone), 1618 (C=Oamide).
7-Chloro-4-oxo-N'-cyclohexyl-1,4-dihydroquinoline-3-carboxamide (11c): yield: 1.8 g (75%) as a
1
white solid; m.p.: 140–141 °C; H-NMR (500.00 MHz, DMSO-d6) δ (ppm): 9.97 (1H, d, J = 7.7 Hz,

Molecules 2014, 19
6662
C=ONH), 8.74 (1H, s, H-2), 8.22 (1H, d, J = 8.7 Hz, H-5), 7.72 (1H, s, H-8), 7.46 (1H, d, J = 8.7 Hz,
H-6), 3.83 (1H, m, H-1'), 1.84 (2H, m, H-2'axial and H-6'axial), 1.67 (2H, m, H-3'axial and H-5'axial),
1.55 (1H, m, H-4'axial), 1.31 (5H, m, H-2'equatorial, H-3'equatorial, H-4'equatorial, H-5'equatorial, H-6'equatorial);
13C-NMR (125.0 MHz, DMSO-d6) δ (ppm): 175.5, 163.1, 144.5, 140.2, 137.0, 127.6, 125.0, 124.8,
118.4, 111.5, 46.7, 32.5, 25.2, 24.1; IR (KBr) ν (cm−1): 3460 (N-Hamide), 3062 (C-Harom), 1630
(C=Oketone), 1570 (C=Oamide).
4-oxo-N'-(4-Chlorophenyl)-1,4-dihydroquinoline-3-carboxamide (12a): yield: 1.3 g (96%) as a bright
1
white solid; m.p.: >300 °C; H-NMR (500.00 MHz, DMSO-d6) δ (ppm): 12.54 (1H, s, C=ONH), 8.86
(1H, s, H-2), 8.32 (1H, dd, J = 8.3 and 1.0 Hz, H-5), 7.82–7.79 (1H, m, H-7), 7.76 (2H, d, J = 8.9 Hz,
H-2' and H-6'), 7.74 (1H, d, J = 8.0 Hz, H-8), 7.53 (1H, m, H-6), 7.39 (2H, d, J = 8.5 Hz, H-3' and H-5');
13C-NMR (125.0 MHz, DMSO-d6) δ (ppm): 176.2, 162.8, 144.1, 138.9, 137.5, 132.9, 128.7, 126.7,
125.7, 125.3, 125.2, 121.0, 119.1, 110.2; IR (KBr) ν (cm−1): 3209 (N-H amide), 3064 (C-H arom),
1665 (C=O ketone), 1626 (C=O amide).
6-Chloro-4-oxo-N'-(4-chlorophenyl)-1,4-dihydroquinoline-3-carboxamide (12b): yield: 1.3 g (98%) as
1
a bright purple solid; m.p.: >300 °C; H-NMR (500.00 MHz, DMSO-d6) δ (ppm): 12.32 (1H, s,
C=ONH), 8.86 (1H, s, H-2), 8.21 (1H, d, J = 2.3 Hz, H-5), 7.81 (1H, dd, J = 8.8 and 2.4 Hz, H-7),
7.76 (1H, d, J = 8.8 Hz, H-8), 7.73 (2H, d, J = 8.8 Hz, H-2' and H-3'), 7.39 (2H, d, J = 8.8 Hz, H-3' and
13
H-5'); C-NMR (125.0 MHz, DMSO-d6) δ (ppm): 175.0, 162.5, 144.4, 137.6, 137.4, 132.9, 129.9,
128.7, 126.9, 126.8, 124.3, 121.5, 121.1, 110.6; IR (KBr) ν (cm−1): 3206 (N-Hamide), 3063 (C-Harom),
1663 (C=Oketone), 1595 (C=Oamide).
4-oxo-N'-(4-Fluorophenyl)-1,4-dihydroquinoline-3-carboxamide (13a): yield: 1.2 g (94%) as a bright
purple solid; m.p.: >300 °C; 1H-NMR (500.00 MHz, DMSO-d6) δ (ppm): 12.47 (1H, s, C=ONH), 8.86
(1H, s, H-2), 8.32 (1H, dd, J = 8.3 and 1.4 Hz, H-5), 7.80 (1H, td, J = 8.3 and 1.4 Hz, H-7), 7.75 (2H, dd,
J = 9.2 and 4.8 Hz, H-2' and H-6'), 7.73 (1H, d, J = 7.8 Hz, H-8), 7.53 (1H, td, J = 8.3 and 0.9 Hz, H-6)
13
7.18 (2H, t, J = 8.8 Hz, H-3' and H-5'); C-NMR (125.0 MHz, DMSO-d6) δ (ppm): 176.2, 162.7,
1
3
158.0 (d, JC-F = 240.0 Hz), 144.0, 139.0, 135.1, 132.8, 125.8, 125.2 (d, JC-F = 7.7 Hz), 121.2, 121.1,
119.1, 115.4 (d, JC-F = 22.1 Hz), 110.3; IR (KBr) ν (cm−1): 3211 (N-Hamide), 3067 (C-Harom),
2
1666 (C=Oketone), 1625 (C=Oamide).
7-Chloro-4-oxo-N'-(4-fluorphenyl)-1,4-dihydroquinoline-3-carboxamide (13b): yield: 1.01 g (80%) as
1
a bright gray solid; m.p.: >300 °C; H-NMR (500.00 MHz, DMSO-d6) δ (ppm): 12.28 (1H, s,
C=ONH), 8.88 (1H, s, H-2), 8.28 (1H, d, J = 8.7 Hz, H-5), 7.77 (1H, d, J = 1.9 Hz, H-8), 7.73 (2H, dd,
J = 9.1 and 4.9 Hz, H-2' and H-6'), 7.53 (1H, dd, J = 8.7 and 1.9 Hz, H-6), 7.18 (2H, d, J = 8.9 Hz, H-3'
and H-5'); 13C-NMR (75.0 MHz, DMSO-d6) δ (ppm): 175.6, 162.3, 159.6, 156.4, 144.7, 139.8, 137.40,
134.9, 127.5, 125.4, 124.4, 121.3, 121.1, 118.3, 115.5, 115.2, 110.9; IR (KBr) ν (cm−1):
3069 (C-Harom), 1664 (C=Oketone), 1614 (C=Oamide); HRMS-ESI (m/z): found for C16H10ClFN2O2
[M+H]+: 317.0488.
4-oxo-N'-(4-Methoxyphenyl)-1,4-dihydroquinoline-3-carboxamide (14a): yield: 1.2 g (86%) as a bright
1
blue solid; m.p.: >300 °C; H-NMR (500.00 MHz, DMSO-d6) δ (ppm): 12.30 (1H, s, C=ONH), 8.85

Molecules 2014, 19
6663
(1H, s, H-2), 8.32 (1H, dd, J = 8.1 and 1.1 Hz, H-5), 7.79 (1H, td, J = 8.3 and 1.4 Hz, H-7), 7.73 (1H,
d, J = 8.1 Hz, H-8), 7.64 (2H, d, J = 9.0 Hz, H-3' and H-5'), 7.52 (1H, t, J = 7.8 Hz, H-6), 6.93 (2H, d,
13
J = 9.0 Hz, H-2' and H-6'), 3.75 (3H, s, OCH3); C-NMR (125.0 MHz, DMSO-d6) δ (ppm): 176.2,
162.3, 155.2, 143.8, 139.0, 132.8, 131.9, 125.8, 125.3, 125.0, 120.9, 119.0, 114.0, 110.6, 55.1;
IR (KBr) ν (cm−1): 3212 (N-H amide), 3064 (C-Harom), 1659 (C=Oketone), 1606 (C=Oamide).
7-Chloro-4-oxo-N'-(4-methoxyphenyl)-1,4-dihydroquinoline-3-carboxamide (14b): yield: 1.14 g (87%)
as a bright purple solid; m.p.: 270–273 °C; 1H-NMR (500.00 MHz, DMSO-d6) δ (ppm): 12.12 (1H, s,
C=ONH), 8.87 (1H, s, H-2), 8.29 (1H, d, J = 8.7 Hz, H-5), 7.78 (1H, d, J = 1.9 Hz, H-8), 7.63 (2H, d,
J = 9.0 Hz, H-3' and H-5'), 7.53 (1H, dd, J = 8.7 and 1.9 Hz, H-6), 6.93 (2H, d, J = 9.0 Hz, H-2' and H-6'),
13
3.87 (3H, s, OCH3); C-NMR (75.0 MHz, DMSO-d6) δ (ppm): 175.6, 161.9, 155.2, 146.5, 139.8,
137.3, 131.7, 127.5, 125.3, 124.4, 120.9, 118.2, 114.0, 111.2, 55.0; IR (KBr) ν (cm−1):
3201 (N-Hamide), 3070 (C-Harom), 1657 (C=Oketone), 1621 (C=Oamide); HRMS-ESI (m/z): found for
C17H13ClN2O3 [M+H]+: 329.0687.
4-oxo-N'-Phenyl-1,4-dihydroquinoline-3-carboxamide (15a): yield: 0.9 g (79%) as a light brown solid;
m.p.: >300 °C; 1H-NMR (500.00 MHz, DMSO-d6) δ (ppm): 12.48 (1H, s, C=ONH), 8.90 (1H, s, H-2),
8.38 (1H, dd, J = 8.1 and 0.9 Hz, H-5), 7.87-782 (1H, m, H-7), 7.78 (1H, m, H-8, H-2' and H-6'),
13
7.57 (1H, m, H-6), 7.40 (2H, t, J = 7.9 Hz, H-3' and H-5'), 7.13 (1H, t, J = 7.4 Hz, H-4'); C-NMR
(125.0 MHz, DMSO-d6) δ (ppm): 176.2, 162.7, 143.9, 139.0, 138.7, 132.8, 128.8, 125.9, 125.4, 125.1,
123.3, 119.5, 119.0, 110.6; IR (KBr) ν (cm−1): 3255 (N-Hamide), 3065 (C-Harom), 1667 (C=Oketone),
1618 (C=Oamide).
6-Chloro-4-oxo-N'-phenyl-1,4-dihydroquinoline-3-carboxamide (15b): yield: 1.0 g (85%) as a bright
white solid; m.p.: >300 °C; 1H-NMR (500.00 MHz, DMSO-d6) δ (ppm): 12.27 (1H, s, C=ONH), 8.88
(1H, s, H-2), 8.23 (1H, d, J = 2.4 Hz, H-5), 7.83 (1H, dd, J = 8.8 and 2.4 Hz, H-7), 7.77 (1H, d, J = 8.8
Hz, H-8), 7.71 (2H, d, J = 8.4 Hz, H-2' and H-6'), 7.36 (2H, t, J = 7.9 Hz, H-3' and H-5'), 7.12-7.07
13
(1H, m, H-4'); C-NMR (125.0 MHz, DMSO-d6) δ (ppm): 175.1, 162.4, 144.5, 138.6, 137.8, 132.9,
128.9, 128.9, 127.0, 124.4, 123.4, 121.6, 119.6, 110.9; IR (KBr) ν (cm−1): 3204 (N-Hamide), 3058 (C-
Harom), 1653 (C=Oketone), 1597 (C=Oamide).
7-Chloro-4-oxo-N'-phenyl-1,4-dihydroquinoline-3-carboxamide (15c): yield: 1.0 g (83%) as a light
brown solid; m.p.: >300 °C; 1H-NMR (500.00 MHz, DMSO-d6) δ (ppm): 12.28 (1H, s, C=ONH), 8.89
(1H, s, H-2), 8.29 (1H, d, J = 8.7 Hz, H-5), 7.77 (1H, d, J = 1.8 Hz, H-8), 7.71 (1H, d, J = 7.6 Hz, H-2' and
H-6'), 7.53 (1H, dd, J = 8.7 and 1.9 Hz, H-6), 7.36 (2H, t, J = 7.9 Hz, H-3' and H-5'), 7.09 (1H, t,
13
J = 7.4 Hz, H-4'); C-NMR (125.0 MHz, DMSO-d6) δ (ppm): 175.7, 162.4, 144.8, 139.8, 138.6,
137.5, 128.9, 127.7, 125.5, 124.6, 123.4, 119.6, 118.3, 111.2; IR (KBr) ν (cm−1): 3204 (N-Hamide), 3069
(C-Harom), 1662 (C=Oketone), 1618 (C=Oamide).
4-Oxo-N'-(p-tolyl)-1,4-dihydroquinoline-3-carboxamide (16a): yield: 1.2 g (94%) as a bright rose
solid; m.p.: >300 °C; 1H-NMR (500.00 MHz, DMSO-d6) δ (ppm): 12.36 (1H, s, C=ONH), 8.84 (1H, s,
H-2), 8.32 (1H, d, J = 8.2 Hz, H-5), 7.80 (1H, t, J = 8.3 Hz, H-7), 7.73 (1H, d, J = 8.2 Hz, H-8), 7.60
(2H, d, J = 8.3 Hz, H-3' and H-5'), 7.52 (1H, t, J = 7.9 Hz, H-6), 7.16 (2H, d, J = 8.3 Hz, H-2' and H-

Molecules 2014, 19
6664
13
6'), 2.27 (3H, s, CH3); C-NMR (125.0 MHz, DMSO-d6) δ (ppm): 176.2, 162.5, 143.9, 139.0, 136.2,
132.8, 132.7, 129.3, 125.8, 125.3, 125.1, 119.5, 119.1, 110.6, 20.3; IR (KBr) ν (cm−1): 3209 (N-Hamide),
3070 (C-Harom), 1663 (C=Oketone), 1604 (C=Oamide).
6-Chloro-4-oxo-N'-(p-tolyl)-1,4-dihydroquinoline-3-carboxamide (16b): yield: 1.19 g (96%) as a
bright gray solid; m.p.: >300 °C; 1H-NMR (500.00 MHz, DMSO-d6) δ (ppm): 12.18 (1H, s, C=ONH),
8.87 (1H, s, H-2), 8.22 (1H, dd, J = 2.3 and 0.7 Hz, H-5), 7.82 (1H, dd, J = 8.9 and 2.3 Hz, H-7), 7.76
(1H, dd, J = 8.9 and 0.7 Hz, H-8), 7.58 (2H, d, J = 8.6 Hz, H-3' and H-5'), 7.16 (2H, d, J = 8.6 Hz, H-2'
13
and H-6'), 2.27 (3H, s, CH3); C-NMR (75.0 MHz, DMSO-d6) δ (ppm): 174.9, 162.1, 144.1, 137.7,
136.0, 132.8, 132.3, 129.7, 129.2, 126.9, 124.2, 121.5, 119.4, 110.9, 20.3; IR (KBr) ν (cm−1):
3155 (N-Hamide), 3065 (C-Harom), 1662 (C=Oketone), 1605 (C=Oamide); HRMS-ESI (m/z): found for
C17H13ClN2O2 [M + H]+: 313.0738; HPLC chromatogram (see Supporting Information).
7-Chloro-4-oxo-N'-(p-tolyl)-1,4-dihydroquinoline-3-carboxamide (16c): yield: 1.07 g (86%) as a green
solid; m.p.: >300 °C; 1H-NMR (500.00 MHz, DMSO-d6) δ (ppm): 12.18 (1H, s, C=ONH), 8.87 (1H, s,
H-2), 8.28 (1H, d, J = 8.8 Hz, H-5), 7.76 (1H, d, J = 1.8 Hz, H-8), 7.59 (2H, d, J = 8.2 Hz, H-3' and H-
5'), 7.52 (1H, dd, J = 8.8 and 1.8 Hz, H-6), 7.15 (2H, d, J = 8.2 Hz, H-2' and H-6'), 2.27 (3H, s, CH3);
13C-NMR (75.0 MHz, DMSO-d6) δ (ppm): 175.5, 162.0, 139.7, 137.3, 135.9, 132.2, 129.1, 127.5,
125.3, 124.4, 119.4, 118.1, 111.1, 20.2; IR (KBr) ν (cm−1): 3205 (N-Hamide), 3069 (C-Harom),
1681 (C=Oketone), 1602 (C=Oamide); HRMS-ESI (m/z): found for C17H13ClN2O2 [M+H]+: 313.0738.
4-Oxo-N'-(2,5-dichlorophenyl)-1,4-dihydroquinoline-3-carboxamide (17a): yield: 1.01 g (66%) as a
light brown solid; m.p.: >300 °C; 1H-NMR (500.00 MHz, DMSO-d6) δ (ppm): 12.98 (1H, s, C=ONH),
8.86 (1H, s, H-2), 8.70 (1H, d, J = 2.6 Hz, H-6'), 8.32 (1H, dd, J = 8.2 and 1.0 Hz, H-5), 7.80 (1H, td,
J = 8.3 and 1.3 Hz, H-7), 7.72 (1H, d, J = 8.2 Hz, H-8), 7.56-7.50 (2H, m, H-3' and H-6), 7.15 (1H, dd,
13
J = 8.6 and 2.6 Hz, H-4'); C-NMR (75.0 MHz, DMSO-d6) δ (ppm): 176.1, 163.5, 144.5, 138.9,
136.99, 133.0, 131.7, 130.4, 125.8, 125.4, 125.3, 123.6, 120.7, 120.6, 119.1, 109.8; IR (KBr) ν (cm−1):
3264 (N-Hamide), 3023 (C-Harom), 1677 (C=Oketone), 1634 (C=Oamide); HRMS-ESI (m/z): found for
C16H10Cl2N2O2 [M+H]+: 333.0192.
6-Chloro-4-oxo-N'-(2,5-dichlorophenyl)-1,4-dihydroquinoline-3-carboxamide (17b): yield: 1.43 g
(98%) as a bright beige solid; m.p.: >300 °C; 1H-NMR (500.00 MHz, DMSO-d6) δ (ppm): 12.74 (1H,
s, C=ONH), 8.85 (1H, s, H-2), 8.65 (1H, d, J = 2.9 Hz, H-6'), 8.20 (1H, d, J = 1.9 Hz, H-5), 7.79 (1H,
dd, J = 8.8 and 1.9 Hz, H-7), 7.73 (1H, d, J = 8.8 Hz, H-8), 7.52 (1H, d, J = 8.8 Hz, H-3'), 7.14 (1H,
13
dd, J = 8.8 and 2.9 Hz, H-4'); C-NMR (75.0 MHz, DMSO-d6) δ (ppm): 175.0, 163.1, 144.8, 137.6,
136.8, 133.0, 131.8, 130.4, 130.0, 126.8, 124.4, 123.7, 121.5, 120.6, 110.2; IR (KBr) ν (cm−1): 3213
(N-Hamide), 3089 (C-Harom), 1659 (C=Oketone), 1619 (C=Oamide); HRMS-ESI (m/z): found for
C16H9Cl3N2O2 [M+H]+: 366.8970; HPLC chromatogram (Supporting Information).
7-Chloro-4-oxo-N'-(2,5-dichlorophenyl)-1,4-dihydroquinoline-3-carboxamide (17c): yield: 0.92 g
(63%) as a bright beige solid; m.p.: >300 °C; 1H-NMR (500.00 MHz, DMSO-d6) δ (ppm): 12.33 (1H,
s, C=ONH), 8.86 (1H, s, H-2), 8.67 (1H, d, J = 2.6 Hz, H-6'), 8.28 (1H, d, J = 9.2 Hz, H-3'), 7.75 (1H,
d, J = 1.9 Hz, H-8), 7.54 (1H, d, J = 8.6 Hz, H-5), 7.50 (1H, dd, J = 8.6 and 1.9 Hz, H-6), 7.15 (1H, dd,

Molecules 2014, 19
6665
J = 8.6 and 2.6 Hz, H-4'); 13C-NMR (75.0 MHz, DMSO-d6) δ (ppm):175.5, 163.0, 145.2, 139.7, 137.4,
136.8, 131.7, 130.3, 127.5, 125.4, 124.4, 123.5, 120.7, 120.6, 118.3, 110.4; IR (KBr) ν (cm−1): 3204
(N-Hamide), 3065 (C-Harom), 1680 (C=Oketone), 1652 (C=Oamide); HRMS-ESI (m/z): found for C16H9Cl3N2O2
[M+H]+: 366.9850.
4-Oxo-N'-(2,5-dimethoxyphenyl)-1,4-dihydroquinoline-3-carboxamide (18a): yield: 0.85 g (57%) as a
1
gray solid; m.p.: 250–251 °C; H-NMR (500.00 MHz, DMSO-d6) δ (ppm): 12.50 (1H, s, C=ONH),
8.89 (1H, s, H-2), 8.32 (1H, dd, J = 8.0 and 1.0 Hz, H-5), 8.21 (1H, d, J = 3.3 Hz, H-6'), 7.80 (1H, td,
J = 8.3 and 1.3 Hz, H-7), 7.71 (1H, d, J = 7.6 Hz, H-8), 7.50 (1H, td, J = 8.3 and 1.3 Hz, H-6), 6.97
(1H, d, J = 8.9 Hz, H-3'), 6.59 (1H, dd, J = 8.6 and 3.0 Hz, H-4'), 3.87 (3H, s, OCH3), 3.71 (3H, s,
13
OCH3); C-NMR (75.0 MHz, DMSO-d6) δ (ppm): 175.9, 162.8, 153.0, 143.9, 142.7, 138.9, 132.7,
129.1, 126.0, 125.4, 125.0, 118.9, 111.6, 110.8, 107.0, 106.8; IR (KBr) ν (cm−1): 3213 (N-Hamide), 3058
(C-Harom), 1666 (C=Oketone), 1633 (C=Oamide); HRMS-ESI (m/z): found for C18H16N2O4 [M+H]+: 325.1183.
6-Chloro-4-oxo-N'-(2,5-dimethoxyphenyl)-1,4-dihydroquinoline-3-carboxamide (18b): yield: 0.62 g
1
(44%) as a bright gray solid; m.p.: 256–258 °C; H-NMR (500.00 MHz, DMSO-d6) δ (ppm): 12.41
(1H, s, C=ONH), 8.87 (1H, s, H-2), 8.21 (1H, d, J = 2.9 Hz, H-6'), 8.26 (1H, d, J = 1.9 Hz, H-5), 7.81
(1H, dd, J = 8.9 and 2.3 Hz, H-7), 7.75 (1H, d, J = 8.9 Hz, H-8), 6.98 (1H, d, J = 8.9 Hz, H-3'), 6.60
(1H, dd, J = 8.9 and 2.9 Hz, H-4'), 3.87 (3H, s, OCH3), 3.71 (3H, s, OCH3); 13C-NMR (75.0 MHz, DMSO-
d6) δ (ppm): 174.7, 162.6, 153.0, 144.9, 142.6, 138.2, 132.6, 129.6, 129.0, 127.1, 124.4, 121.8, 111.5,
111.0, 107.0, 106.8, 56.4, 55.2; IR (KBr) ν (cm−1): 3154 (N-Hamide), 3090 (C-Harom), 1721 (C=Oketone),
1695 (C=Oamide); HRMS-ESI (m/z): found for C18H15ClN2O4 [M+H]+: 359.0793.
7-Chloro-4-oxo-N'-(2,5-dimethoxyphenyl)-1,4-dihydroquinoline-3-carboxamide (18c): yield: 0.64 g
1
(45%) as a gray solid; m.p.: 261–262 °C; H-NMR (500.00 MHz, DMSO-d6) δ (ppm): 12.38 (1H, s,
C=ONH), 8.87 (1H, s, H-2), 8.31 (1H, d, J = 8.6 Hz, H-5), 8.19 (1H, d, J = 3.3 Hz, H-6'), 7.75 (1H, d,
J = 1.9 Hz, H-8), 7.51 (1H, dd, J = 8.6 and 1.9 Hz, H-6), 6.98 (1H, d, J = 8.9 Hz, H-3'), 6.59 (1H, dd,
J = 8.9 and 2.9 Hz, H-4'), 3.87 (3H, s, OCH3), 3.71 (3H, s, OCH3); 13C-NMR (75.0 MHz, DMSO-d6) δ
(ppm): 175.4, 162.5, 153.0, 144.9, 142.7, 139.9, 137.2, 128.9, 127.7, 125.3, 124.7, 118.3, 111.6, 111.4,
107.0, 106.8, 56.4, 55.2; IR (KBr) ν (cm−1): 3401 (N-Hamide), 3071 (C-Harom), 1654 (C=Oketone),
1623 (C=Oamide); HRMS-ESI (m/z): found for C18H15ClN2O4 [M+H]+: 359.0793.
3.3. Instrumental Parameters for HPLC
The HPLC analysis of the active 4-oxoquinoline-3-carboxamide derivatives 16b and 17b was
carried out by injecting 20 μL of a 25.6 μmol·L−1 standard solution of 16b and 21.7 μmol·L−1 standard
solution of 17b, using acetonitrile as mobile phase pumped at a flow rate of 1 mL·min−1. The
temperature of the column was set at 20 °C (see Supporting Information).
3.4. Molecular Docking Studies
Docking studies were performed using the GOLD program on a Windows-based PC. The
three-dimensional structure of 16b and 17b were built and minimized to the PM6 level on the
molecular modeling program Spartan’10 (Wavefunction Inc., Irvine, CA, USA). The coordinates of

Molecules 2014, 19
6666
the protein crystal structure were obtained from the Protein Data Bank (PDB code 3QX3). The ligand
etoposide and solvent molecules were removed. Hydrogen atoms were added, and non-hydrogen atoms
were merged with the polar respective carbon atoms. Taking the prepared protein and ligand, GOLD
docking calculations were performed using standard parameters. The scoring function used during
GOLD docking was Goldscore. For each of the 100 independent genetic algorithm (GA) runs, with a
selection pressure of 1.1, 10.000 GA operations were performed on a set of five islands with a
population size of 100 individuals. Default operator weights were used for crossover, mutation, and
migration of 95, 95, and 10, respectively. To expedite the calculations, the GA docking was terminated
when the top three solutions were within 1.5 Å RMSD. All other values were set to the default [31,32].
Finally, eighty top ranked positions (or conformations) were saved.
3.5. DNA Relaxation Assay
Human topoisomerase IIα (TopoIIα) was obtained from TopoGEN, Inc. (Columbus, OH, USA).
Proteinase K from Tritirachium album was obtained from Sigma-Aldrich, Inc. (St. Louis, MO, USA)
and was dissolved in DNase free water. A TAE gel electrophoresis buffer was used in this assay.
The inhibitory effects of the derivatives on human TopoIIα were measured using a Eukaryotic
Topoisomerase II Drug Screening Kit (TopoGEN, Inc.). All derivatives were dissolved in DMSO
immediately prior to testing.
The substances were tested at a fixed concentration of 0.1 mM. This assay concentration was
chosen based on the effective concentration of the VP-16 (etoposide) standard (0.1 mM), as
recommended by the kit manufacturer (TopoGen). To ensure that DMSO did not interfere in the
experiment, different concentrations of DMSO were tested. There was no interference in enzyme
function with concentrations from 0%–5% DMSO. Supercoiled plasmid DNA (pRYG, 200 ng) was
incubated with human TopoIIα (10 U) at 37 °C for 30 min in relaxation buffers in the absence or
presence of derivatives (final volume is 20 μL). The order of reagent addition was buffer, test
derivative, Topo IIα and finally DNA.
The assay samples were analyzed by electrophoresis on a 1% agarose gel without EtdBr (25 V, 18 h,
room temperature) in TAE buffer, followed by staining in 0.5 μg/mL of EtdBr to allow for observation
of the DNA bands under UV light.
3.6. In Silico Pharmacokinetics and Toxicity Analysis
For this analysis, we used Osiris Property Explorer [33] to predict the physicochemical properties
(cLogP, solubility), toxicity and “druglikeness” of the most actives derivatives, 16b and 17b. Values of
“druglikeness” are based on the frequency of occurrence of each fragment of the molecule in
commercial drugs, and the drug score evaluates the derivative’s potential to qualify as a drug and is
related to topological descriptors, fingerprints of molecular “druglikeness”, structural keys and other
properties such as cLog P, log S and molecular weight.

Molecules 2014, 19
6667
3.7. Anticancer Assays
3.7.1. Cytotoxicity against Cancer Cell Lines
The 4-oxoquinoline-3-carboxamide derivatives (0.3125–20 μM) were tested for cytotoxic activity
against three cancer cell lines: HCT-116 (colon), ACP03 (gastric), and MDAMB-231 (breast) (Table 1).
Active derivatives were also tested against a normal fibroblast cell line (MRC-5). All cell lines
were maintained in DMEM medium supplemented with 10% fetal bovine serum, 2 mM glutamine,
100 U/mL penicillin, and 100 µg/mL streptomycin and were incubated at 37 °C with 5% CO2. Each
derivative was dissolved with DMSO to a concentration of 10 mM. The final concentration of DMSO
in the culture medium was kept at a constant value below 0.1% (v/v). The derivatives (0.3125–20 µM)
were incubated with the cells for 72 h. The negative control contained the same amount of DMSO
(0.001% maximum). Cell viability was determined by the reduction of the yellow dye 3-(4,5-dimethyl-
2-thiazol)-2,5-diphenyl-2H-tetrazolium bromide (MTT) to a blue formazan product as described by
Mosmann [34].
3.7.2. Cell Membrane Disruption
The assay was performed in 96-well plates using a 2% mouse erythrocyte suspension in 0.85%
NaCl containing 10 mM CaCl2. Derivatives 10–18, diluted as described above, were tested at
250 µg/mL. After incubation at room temperature for 1 h and centrifugation, the supernatant was
removed, and the liberated hemoglobin was measured spectrophotometrically at 540 nm. DMSO was
used as a negative control, and Triton X-100 (1%) was used as a positive control.
3.7.3. Analysis of the Results
In the MTT experiments, the results were analyzed according to their means and standard errors in
the program GraphPad Prism. Each sample was analyzed in triplicate.
4. Conclusions
In this work, we synthesized a new series of 4-oxoquinoline derivatives that exhibited significant
antitumor activity against gastric cancer cells. In vitro studies showed that the mechanism of action of
16b is related to topoisomerase II inhibition, which was corroborated by in silico studies. 16b and 17b
were more selective to cancer cells compared to doxorubicin, and these results may contribute to the
design of novel anticancer derivatives with fewer side effects.
Supplementary Materials
Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/19/5/6651/s1.
Acknowledgments
We acknowledge FAPERJ, CNPQ, CAPES, and UFF for financial support and fellowships.

Molecules 2014, 19
6668
Author Contributions
Luana da S. M. Forez: Synthetic work, discussion of results, writing of the manuscript; Nathalia M.
C. Tolentino: Synthetic work; Alessandra M. T. de Souza: Molecular docking validation and In Silico
Pharmacokinetic Analysis; Helena C. Castro: Molecular docking, discussion of results, writting of the
manuscript; Raquel C. Montenegro: Biological experiments, discussion of results, writing of the
manuscript; Rafael F. Dantas: Execution and analysis of Topoisomerase assay results; Maria E. I. M.
Oliveira: Execution of Topoisomerase assays; Floriano P. Silva, Jr.: Responsible for the experimental
design and analysis of Topoisomerase assay results; Leilane H. Barreto: Cytotoxic experiments;
Rommel M. R. Burbano: Biological experiments and writing of the manuscript; Bárbara Abrahim-
Vieira: Molecular Docking and analysis of 17b at topoisomerase II; Riethe de Oliveira: Molecular
Docking and analysis of 16b at topoisomerase II; Vitor F. Ferreira: Planning, synthetic work,
discussion of results and conclusions, writing of the manuscript; Anna C. Cunha: Planning, synthetic
work, discussion of results and conclusions, writing of the manuscript; Fernanda da C. S. Boechat:
Planning, synthetic work, discussion of results and conclusions, writing of the manuscript; Maria
Cecília B. V. de Souza: Planning, synthetic work, discussion of results and conclusions, writing of
the manuscript.
Conflicts of Interest
The authors declare no conflict of interest.
References and Notes
1. Suthar, S.K.; Jaiswal, W.; Lohan, S.; Bansal, S.; Chaudhary, A.; Tiwari, A.; Alex, A.T.; Joesph, A.
Novel quinolone substituted thiazolidin-4-ones as anti-inflammatory, anticancer agents: Design,
synthesis and biological screening. Eur. J. Med. Chem. 2013, 63, 589–602.
2. Mitscher, L.A. Bacterial topoisomerase inhibitors: Quinolone and pyridone antibacterial agents.
Chem. Rev. 2005, 105, 559–592.
3. Ahmed, A.; Daneshtalab, M. Nonclassical Biological Activities of Quinolone Derivatives.
J. Pharm. Pharm. Sci. 2012, 15, 52–72.
4. Mugnaini, C.; Pasquini, S.; Corelli, F. The 4-quinolone-3-carboxylic acid motif as a multivalent
Scaffold in Medicinal Chemistry. Curr. Med. Chem. 2009, 16, 1746–1767.
5. Audisio, D.; Messaoudi, S.; Peyrat, J.F.; Brion, J.D.; Alami, M.J. A general copper powder-catalyzed
ullmann-type reaction of 3-halo-4(1H)-quinolones with variousnitrogen-containingnucleophiles.
J. Org. Chem. 2011, 76, 4995–5005.
6. Xia, Y.; Yang, Z.; Xia, P.; Hackl, T.; Hamel, E.; Mauger, A.; Wu, J.; Lee, K. Antitumor agents.
211. Fluorinated 2-phenyl-4-quinolone derivatives as antimitotic antitumor agents. J. Med. Chem.
2001, 44, 3932–3936.
7. Abbas, J.A.; Stuart, R.K. Vosaroxin: A novel antineoplasic quinolone. Expert Opin. Investig.
Drugs 2012, 21, 1223–1233.

Molecules 2014, 19
6669
8. Advani, R.H.; Hurwitz, H.I.; Gordon, M.S.; Ebbinghaus, S.W.; Mendelson, D.S.; Wakelee, H.A.
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors:
A report on two dosing schedules. Clin. Cancer Res. 2010, 16, 2167–2175.
9. Lai, Y.; Huang, L.; Lee, K.; Xiao, Z.; Bastow, K.F.; Yamiri, T.; Kuo, S. Synthesis and biological
relationships of 3',6-substituted 2-phenyl-4-quinolone-3-carboxylic acid derivatives as antimitotic
agents. Bioorg. Med. Chem. 2005, 13, 265–275.
10. Rajabalian, S.; Foroumadi, A.; Shafiee, A.; Emami, A. Functionalized N-(2-oxyiminoethyl)
piperazinyl quinolones as new cytotoxic agents. J. Pharm. Pharm. Sci. 2007, 10, 153–158.
11. Abe, H.; Kawada, M.; Inoue, H.; Ohba, S.; Nomoto, A.; Watanabe, T.; Shibasaki, M. Synthesis of
intervenolin, an antitumor natural quinolone with unusual substituents. Org. Lett. 2013, 15,
2124–2127.
12. Hawtin, R.E.; Stockett, D.E.; Byl, J.A.W.; Mcdowell, R.S.; Tan, N.; Arkin, M.R. Structural
biology of human H3K9 methyltransferases. PLoS One 2010, 5, e8570.
13. Foroumadi, A.; Emami, S.; Rajabalian, S.; Badinloo, M.; Mohammdhosseini, N.; Shafiee, A.
N-Substituted piperazinyl quinolones as potential cytotoxic agents: Structure-activity
relationships study. Biomed. Pharmacother. 2009, 63, 216–220.
14. Chen, Y.; Chung, C.; Chen, I.; Chen, P.; Jeng, H. Synthesis and cytotoxic activity evaluation of
indolo-, pyrrolo-, and benzofuro-quinolin-2(1H)-ones and 6-anilinoindoloquinoline derivatives.
Bioorg. Med. Chem. 2002, 10, 2705–2712.
15. Sabbah, D.; Simms, N.; Wang, W.; Dong, Y.; Ezell, E.L.; Brattain, M.G.; Vennerstrom, J.L.;
Zhong, H.A. N-Phenyl-4-hydroxy-2-quinolone-3-carboxamides as selective inhibitors of mutant
H1047R phosphoinositide-3-kinase (PI3Kα). Bioorg. Med. Chem. 2012, 20, 7175–7183.
16. Voreloxin is not in the market (but in clinical trial) and literature still ask about its ability of
replacing the anthracycline drugs, requesting future investigation to confirm its efficacy.
Altogether these data point doxorubicin as the best control drug to compare our active
experimental profile against cancer cell lines, see: Freeman, C.; Keane, N.; Swords, R.; Giles, F.
Vosaroxin: A new valuable tool with the potential to replace anthracyclines in the treatment of
AML? Expert Opin. Pharmacother. 2013, 14, 1417–1427.
17. Gould, R.G.; Jacobs, W.A. The Synthesis of Certain Substituted Quinolines and 5,6-Benzoquinolines.
J. Am. Chem. Soc. 1939, 61, 2890–2895.
18. Snyder, H.R.; Freier, H.E.; Kovacic, P.; Heyningen, E.M.V. Synthesis of 4-hydroxyquinolines.
VIII. Some halogen containing 4-aminoquinoline derivatives. J. Am. Chem. Soc. 1947, 69, 371–373.
19. Stern, E.; Muccioli, G.G.; Millet, R.; Goossens, J.-F.; Farce, A.; Chavatte, P.; Poupaert, J.H.;
Lambert, D.M.; Depreux, P.; Hénichart, J.-P. Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide
derivatives as new CB2 cannabinoid receptors agonists: Synthesis, pharmacological properties,
and molecular modeling. J. Med. Chem. 2006, 49, 70–79.
20. Riegel, B.; Lappin, G.R.; Adelson, B.H.; Jackson, R.I.; Albisetti C.J., Jr.; Dodson, R.M.; Baker, R.H.
The synthesis of some 4-quinolinols and 4-chloroquinolines by the ethoxymethylenemalonic ester
method. J. Am. Chem. Soc. 1946, 68, 1264–1266.
21. Matta, A.D.; Bernardino, A.M.R.; Romeiro, G.A.; Oliveira, M.R.P.; Souza, M.C.B.V.; Ferreira, V.F.
Nucleosides having quinolone derivatives as nitrogenated base: Regiospecific and stereospecific

Molecules 2014, 19
6670
ribosylation of 3-carbethoxy-1,4-dihydro-4-oxoquinolines. Nucleos. Nucleot. Nucleic Acids 1996,
15, 889–898.
22. Doxorubicin is one of the most important anticancer chemotherapeutic drug currently in use.
Importantly, despite of its side effects, it is still in use and new formulations options are still being
investigated due to its significant therapeutic profile, see: Deepa, K.; Singha, S.; Panda, T.J.
doxorubicin nanoconjugates. Nanosci. Nanotechnol. 2014, 14, 892–904.
23. Wu, C.C.; Li, T.K.; Farh, L.; Lin, L.Y.; Lin, T.S.; Yu, Y.J.; Yen, T.J.; Chiang, C.W.; Chan, N.L.
Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Science
2011, 333, 459–462.
24. Esteves-Souza, A.; Rodrigues-Santos, C.E.; del Cistia, C.N.; Silva, D.R.; Sant’anna, C.M.R.;
Echevarria, A. Solvent-free synthesis, DNA-topoisomerase II activity and molecular docking
study of new asymmetrically N,N'-substituted ureas. Molecules 2012, 17, 12882–12894.
25. Lipinski, C.A. Lead- and drug-like compounds: The rule-of-five revolution. Drug Discov.
Today Technol. 2004, 4, 337–341.
26. Gajbhiye, A.; Chaturvedi, L. Synthesis of 4-quinolones derivatives for their antihistaminic
activity. Int. J. Pharm. Pharm. Sci. 2013, 5, 223–227.
27. Shah, K.J.; Coats, E.A. Design, synthesis, and correlation analysis of 7-Substituted4-
hydroxyquinoline-3-carboxylic acids as inhibitors of cellular respiration. J. Med. Chem. 1977, 20,
1001–1006.
28. Wathen, L.K.; Wathen, L.M. Method of Preventing or Treating Atherosclerosis or Restenosis.
U.S. Patent WO2004019932 (A1), 11 March 2004.
29. Sheth, U.; Fanning, T.T.D.; Numa, M.; Binch, H.; Hurley, D.J.; Zhou, J.; Hadida, R.S.S.;
Hazlewood, A.R.; Silina, A.; Vairagoundar, R.; et al. 4-Oxo-1H-Quinoline-3-Carboxamides as
Modulators of ATP-Binding Cassette Transporters. U.S. Patent WO2011072241 (A9), 16 June 2011.
30. Singh, A.; van Goor, F.; Worley, L.J.F.; Jennings, F.; Knapp, T. Compounds Useful in Cftr
Assays and Methods Therewith. U.S. Patent WO 2007075946 (A1), 5 July 2007.
31. Verdonk, M.L.; Berdini, V.; Hartshorn, M.L.; Mooij, W.T.; Murray, C.W.; Taylor, R.D.; Watson, P.
Virtual screening using protein-ligand docking: Avoiding artificial enrichment. J. Chem. Inf.
Comput. Sci. 2004, 44, 793–806.
32. Verdonk, M.L.; Cole, J.C.; Hartshorn, M.J.; Murray, C.W.; Taylor, R.D. Improved protein–ligand
docking using GOLD. Proteins: Struct. Funct. Genet. 2003, 52, 609–623.
33. Sander, T. Actelion Pharmaceuticals Ltd. Available online: http://www.organic-chemistry.org/
(accessed on 13 May 2014).
34. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to
proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55–63.
Sample Availability: Samples of the compounds 10–18 are available from the authors.
© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/3.0/).